Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics, Inc. (TNGX)
NASDAQ:TNGX
TNGX Stock Chart & Stats
$13.01
-$0.22(-6.34%)
At close: 4:00 PM EST
$13.01
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$1.03 - $13.18
Previous CloseN/A
Volume187.94K
Average Volume (3M)2.77M
Market Cap
$1.57B
Enterprise Value$908.54M
Total Cash (Recent Filing)$152.81M
Total Debt (Recent Filing)$34.76M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 30, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding134,677,100
10 Day Avg. Volume3,593,086
30 Day Avg. Volume2,767,882
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)1.69
Price to Sales (P/S)8.02
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue13.66
Enterprise Value/Gross Profit13.91
Enterprise Value/Ebitda-8.74
Forecast
1Y Price Target
$13.71Price Target Upside5.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$8.42M
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressA pivotal Phase 3 trial for vopimetostat vs. chemo in 2L MTAP-deleted PDAC patients is set to be initiated, indicating progress in clinical trials.
Combination Therapy PotentialThe synergy potential in combining vopimetostat with daraxonrasib could drive durable disease control and overcome RASi resistance.
Financial StabilityWith anticipated gross proceeds of $225 million from a registered deal and PIPE financing, Tango Therapeutics expects to have a cash runway into 2028, supporting its continued development efforts.
Bears Say
Clinical RisksRisks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates into registrational trials.
Regulatory ChallengesThere is a risk of failure to achieve favorable clinical results with other candidates, specifically TNG456, and the inability to obtain regulatory approvals in a timely manner.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics, Inc.’s price range in the past 12 months?
Tango Therapeutics, Inc. lowest stock price was $1.03 and its highest was $13.18 in the past 12 months.
What is Tango Therapeutics, Inc.’s market cap?
Tango Therapeutics, Inc.’s market cap is $1.57B.
When is Tango Therapeutics, Inc.’s upcoming earnings report date?
Tango Therapeutics, Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 71 days.
How were Tango Therapeutics, Inc.’s earnings last quarter?
Tango Therapeutics, Inc. released its earnings results on Nov 04, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.051 by $0.191.
Is Tango Therapeutics, Inc. overvalued?
According to Wall Street analysts Tango Therapeutics, Inc.’s price is currently Undervalued.
Does Tango Therapeutics, Inc. pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
What is Tango Therapeutics, Inc.’s EPS estimate?
Tango Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has 134,677,100 shares outstanding.
What happened to Tango Therapeutics, Inc.’s price movement after its last earnings report?
Tango Therapeutics, Inc. reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.051. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tango Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.71 (5.38% Upside)
$13.71 (5.38% Upside)
Blogger Sentiment
Bullish
TNGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 18.2%
Last 30 Days ▲ 18.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
367.98%
12-Months-Change
Fundamentals
Return on Equity
-51.65%
Trailing 12-Months
Asset Growth
-40.37%
Trailing 12-Months
Company Description
Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$13.71
▲(5.38% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---